Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds already developed in immuno-oncology, now expected ...

Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

That said, I also cited a quote from a co-moderator of that study ... in February this year, Boehringer Ingelheim and Zealand Pharma's GLP-1 agonist drug reported data from a Phase 2 study in ...

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

1965 - On 5th February, the Company entered into an agreement with C.H. Boehringer Sohn, Ingelheim am Rhein (also known as Hoehringer Ingelheim GmbH) who agreed to give the Company free of royalty ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

This new ticker symbol will replace the Company’s previous ticker symbol “TCJH”. No action by the Company’s shareholders is required with respect to the ticker symbol change. The Company's ...